Skip to main content

ENSAYO CLINICO FASE II SOBRE EL USO DE UN CART HUMANIZADO DIRIGIDO CONTRA BCMA (ARI0002H) EN PACIENTES CON MIELOMA MULTIPLE RECAIDO/REFRACTARIO A INHIBIDORES DEL PROTEASOMA, INMUNOMODULADORES Y ANTICUERPOS ANTI-CD38

ICI19/00025

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación Clínica Independiente
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

  • Zugasti, Inés
  • Tormo-Ratera, Marta
  • Oliver-Caldés, Aina
  • Soler-Perromat, Juan Carlos
  • González-Calle, Verónica
  • Moreno, David F.
  • Cabañas, Valentín
  • López-Muñoz, Nieves
  • Bartolomé-Solanas, Álvaro
  • Español-Rego, Marta
  • Reguera-Ortega, Juan Luis
  • Rosiñol, Laura
  • López-Corral, Lucía
  • Tovar, Natalia
  • Rodríguez-Lobato, Luis Gerardo
  • Álvarez-Pérez, Rosa María
  • Varea, Sara
  • Olesti, Eulalia
  • Gómez-Grande, Adolfo
  • Frutos, Laura
  • Tamayo, Pilar
  • Juan, Manel
  • Moraleda, José María
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Azucena
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Tomás, Xavier
  • Setoain, Xavier
  • Fernández de Larrea, Carlos
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]-targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11., This study was supported by grants from the Instituto de Salud Carlos III (cofounded by the European Union) and the Spanish Ministry of Health (ICI19/00025 and PI22/00647), the RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019, RD21/0017/0001, RD21/0017/0006 and RD21/0017/0030), Red de Terapia Celular TERCEL (RD16/0011/0005), Fondo Europeo de Desarrollo Regional, 2021-SGR-01292 (AGAUR; Generalitat de Catalunya), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), La Caixa Foundation (CP042702/LCF/PR/GN18/50310007), Asociación Española Contra el Cancer LABAE21971FERN, and Fundació Bosch I Aymerich support. A.O.-C. from the resident grant Ajut Clínic-La Pedrera 2019, granted by Hospital Clínic de Barcelona. L.G.R.-L. has received funding from the CRIS Cancer Foundation (project number: PR_TMT_2023-6)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells

  • Battram, Anthony M|||0000-0002-9179-0639
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Suárez Lledó, Maria
  • Lozano, Miquel|||0000-0003-2593-833X
  • Bosch, Miquel|||0000-0002-7103-2574
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Cid, Joan|||0000-0001-5445-4508
  • Moreno, David F.
  • Rodríguez Lobato, Luis Gerardo|||0000-0001-5694-0921
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at which stage the endogenous T cells used to produce the CAR-T cells are affected by the immunosuppressive nature of advanced MM and/or side effects of previous therapies. An alternative pool of "fitter" T cells is found in leukocytoapheresis products that are routinely collected to obtain hematopoietic progenitor cells for autologous stem cell transplantation (ASCT) early in the treatment of MM. However, to mobilize the progenitor cells, patients are dosed with granulocyte colony-stimulating factor (G-CSF), which is reported to adversely affect T cell proliferation, function, and differentiation. Here, we aimed to first establish whether G-CSF treatment negatively influences T cell phenotype and to ascertain whether previous exposure of T cells to G-CSF is deleterious for anti-BCMA CAR-T cells. We observed that G-CSF had a minimal impact on T cell phenotype when added in vitro or administered to patients. Moreover, we found that CAR-T cell fitness and anti-tumor activity were unaffected when generated from G-CSF-exposed T cells. Overall, we showed that ASCT apheresis products are a suitable source of T cells for anti-BCMA CAR-T cell manufacture.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Il-15 enhances the persistence and function of bcma-targeting car-t cells compared to il-2 or il-15/il-7 by limiting car-t cell dysfunction and differentiation

  • Battram, Anthony M.|||0000-0002-9179-0639
  • Bachiller, Mireia|||0000-0002-6153-4722
  • Lopez, Victor
  • Fernandez de Larrea Rodriguez, Carlos
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a year of receiving the therapy. Increased persistence and reduced dysfunction are crucial features that enhance the durability of CAR-T cell responses. One of the factors that influence CAR-T cell in vivo longevity and loss of function, but which has not yet been extensively studied for BCMA-directed CAR-T cells, are the cytokines used during their production. We here compared the impact of IL-2, IL-15 and a combination of IL-15/IL-7 on the phenotype and function of ARI2h, an academic BCMA-directed CAR-T cell that is currently being administered to MM patients. For this study, flow cytometry, in vitro cytotoxicity assays and analysis of cytokine release were performed. In addition, ARI2h cells expanded with IL-2, IL-15, or IL-15/IL-7 were injected into MM tumor-bearing mice to assess their in vivo efficacy. We demonstrated that each of the cytokine conditions was suitable for the expansion of ARI2h cells, with clear in vitro activity. Strikingly, however, IL-15-produced ARI2h cells had improved in vivo efficacy and persistence. When explored further, it was found that IL-15 drove a less-differentiated ARI2h phenotype, ameliorated parameters related to CAR-T cell dysfunction, and lowered the release of cytokines potentially involved in cytokine release syndrome and MM progression. Moreover, we observed that IL-15 was less potent in inducing T cell senescence and DNA damage accumulation, both of which may contribute to an unfavorable CAR-T cell phenotype. These findings show the superiority of IL-15 to IL-2 and IL-15/IL-7 in the quality of anti-BCMA CAR-T cells, particularly their efficacy and persistence, and as such, could improve the duration of responses if applied to the clinical production of CAR-T cells for patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities, Laboratory tools for an early and differential diagnosis

  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Fernández, Sara
  • Ventosa-Capell, Helena
  • Palomo, Marta|||0000-0002-3261-6577
  • Martínez Sánchez, Julia
  • Ramos, Alex|||0000-0003-1333-5144
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Delgado, Julio|||0000-0002-5157-4376
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Penack, Olaf|||0000-0003-4876-802X
  • Nicolás, J.M.
  • Téllez, Adrian
  • Escolar, Ginès
  • Carreras, Enric|||0000-0002-3134-9964
  • Fernandez Aviles, Francesc|||0000-0003-3051-3926
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in which the endothelium could be a pathophysiological substrate. Furthermore, differential diagnosis from sepsis, highly incident in these patients, is challenging. Suitable laboratory tools could be determinant for their appropriate management. Methods Sixty-two patients treated with CAR-T cell immunotherapy for hematological malignancies (n=46 with CD19-positive diseases, n=16 with multiple myeloma) were included. Plasma samples were obtained: before CAR-T cell infusion (baseline); after 24-48 hours; at suspicion of any toxicity onset and 24-48 hours after immunomodulatory treatment. Biomarkers of endothelial dysfunction (soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble TNF receptor 1 (sTNFRI), thrombomodulin (TM), soluble suppression of tumorigenesis-2 factor (ST2), angiopoietin-2 (Ang-2)), innate immunity activation (neutrophil extracellular traps (NETs), soluble C5b-9 (sC5b-9)) and hemostasis/fibrinolysis (von Willebrand Factor antigen (VWF:Ag), ADAMTS-13 (A13), α2-antiplasmin (α2-AP), plasminogen activator inhibitor-1 antigen (PAI-1 Ag)) were measured and compared with those in cohorts of patients with sepsis and healthy donors. Results Patients who developed CAR-T cell toxicities presented increased levels of sVCAM-1, sTNFRI and ST2 at the clinical onset versus postinfusion values. Twenty-four hours after infusion, ST2 levels were good predictors of any CAR-T cell toxicity, and combination of ST2, Ang-2 and NETs differentiated patients requiring intensive care unit admission from those with milder clinical presentations. Association of Ang-2, NETs, sC5b-9, VWF:Ag and PAI-1 Ag showed excellent discrimination between severe CAR-T cell toxicities and sepsis. Conclusions This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.